Core Scientific (CORZ) grants 18,575 RSUs to board director
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Core Scientific director Jeffrey David Booth received 18,575 restricted stock units of common stock on February 4, 2026, as reported in a Form 4 filing. The grant was priced at $0 per share and will vest in full on February 3, 2027, if he continues serving as a non-employee director through that date. Following this award, Booth beneficially owns 214,262 shares of Core Scientific common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Booth Jeffrey David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 18,575 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 214,262 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Core Scientific (CORZ) report for Jeffrey David Booth?
Core Scientific reported that director Jeffrey David Booth received 18,575 shares of common stock through a restricted stock unit grant. The award was recorded at a price of $0 per share and increased his directly owned stake to 214,262 shares after the transaction.
When do Jeffrey David Booth’s Core Scientific RSUs vest?
Jeffrey David Booth’s restricted stock units from Core Scientific vest in full on February 3, 2027. Vesting requires that he continue to provide service to the company as a non-employee director through that date, according to the Form 4 footnote.
What type of equity award did Core Scientific grant to Jeffrey David Booth?
Core Scientific granted Jeffrey David Booth a restricted stock unit, or RSU, award covering 18,575 shares of common stock. RSUs are share-based awards that convert into stock upon vesting, which in this case is scheduled for February 3, 2027, subject to continued service.
Was there a purchase price for Jeffrey David Booth’s Core Scientific RSU grant?
No cash purchase price was paid for Jeffrey David Booth’s restricted stock unit grant from Core Scientific. The Form 4 shows 18,575 shares acquired at a transaction price of $0 per share, reflecting a compensatory equity award rather than an open-market purchase.
What is Jeffrey David Booth’s role at Core Scientific (CORZ) in this filing?
In this filing, Jeffrey David Booth is identified as a director of Core Scientific. The RSU grant he received is tied to his service as a non-employee director, and continued board service through February 3, 2027 is required for the award to fully vest.